Sanofi Completes Acquisition Of Blueprint Medicines
Reuters
Jul 18
July 18 (Reuters) - Sanofi SA :: *SANOFI COMPLETES ACQUISITION OF BLUEPRINT MEDICINES *TENDER OFFER FOR BLUEPRINT SHARES EXPIRED JULY 17, 2025 *ACCEPTED PAYMENT FOR ALL VALIDLY TENDERED SHARES *ACQUISITION INCLUDES AYVAKIT APPROVED IN US AND EU *BLUEPRINT STOCK WILL CEASE TRADING ON NASDAQ
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.